First Andro Gel (Low-Testosterone) Trial: $150M Verdict
Abb Vie Ordered to Pay $150 Million Damages in `Low T' Trial
AbbVie Inc was ordered to pay $150 million to an Oregon man who accused the drug maker of hiding the heart attack risks of its AndroGel testosterone booster, but the company’s first trial loss probably won’t stand because jurors awarded no compensation for injuries.